I did some research on products that may be in a similar position, regarding emergency use authorization
Here's an interesting chronology:
So the research for the clinical evaluation of this covid diagnistic test was published AFTER the device was given emergency use authorisation....
eg.
date research was published: Jul 6 2020
date authorisation was obtained: May 1 2020
date FDA permits marketing of diagnostic test: March 17 2021
I think this gives a bit of perspective in regards to NANOSEMED and DiaNose
---
https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-first-sars-cov-2-diagnostic-test-using-traditional-premarket-review-process
FDA Permits Marketing of First SARS-CoV-2 Diagnostic Test Using Traditional Premarket Review Process
Today, the U.S. Food and Drug Administration granted marketing authorization of the BioFire Respiratory Panel 2.1 (RP2.1), a diagnostic test for the simultaneous qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs (NPS) obtained from individuals suspected of COVID-19 and other respiratory tract infections. The diagnostic test, which had an Emergency Use Authorization (EUA), was granted marketing authorization using the De Novo premarket review pathway, a regulatory pathway for low- to moderate-risk devices of a new type. The grant of this De Novo request marks an important step in FDA’s response to the COVID-19 pandemic because it is the first SARS-CoV-2 diagnostic test that will be permitted to be marketed beyond the public health emergency.
https://www.accessdata.fda.gov/cdrh_docs/pdf20/DEN200031.pdf
https://pubmed.ncbi.nlm.nih.gov/32650276/
2020 Jul 6
Clinical evaluation of the BioFire® Respiratory Panel 2.1 and detection of SARS-CoV-2
Abstract
We evaluated the performance of the BioFire® Respiratory Panel 2.1 (RP2.1) in the detection of SARS CoV-2 in comparison against three other SARS CoV-2 EUA assays. In these studies, the RP2.1 panel had 98 % positive percent agreement (48/49) and 100 % negative percent agreement (49/49). Since 30 % of nasopharyngeal swab specimens have a SARS CoV-2 Ct >30 and thus detection of virus in low titers is clinically relevant, a sample with a high titer was diluted and each 10 fold dilution was tested in triplicate and compared against 6 other EUA approved SARS CoV-2 assays. These data suggested that the BioFire® RP2.1 panel, along with four other SARS CoV-2 assays (Roche cobas, Cepheid Xpert Xpress, BioFire® Defense COVID19, and NECoV19), consistently detected viral RNA at the 10-7 dilution. Overall, these studies suggest that the BioFire® RP2.1 assay can be used to detect acute cases of SARS CoV2 in addition to patients with low viral titer later in disease presentation.
BIOFIRE® Respiratory 2.1 (RP2.1) Panel with SARS-CoV-2 Obtains De Novo FDA Authorization
This De Novo authorization will be concurrent with the revocation of the U.S. FDA EUA that was obtained on May 1st, 2020 for this panel.
- Forums
- ASX - By Stock
- BRN
- May
May, page-57
Featured News
Add BRN (ASX) to my watchlist
(20min delay)
|
|||||
Last
24.5¢ |
Change
-0.030(10.9%) |
Mkt cap ! $480.8M |
Open | High | Low | Value | Volume |
26.0¢ | 27.0¢ | 24.0¢ | $4.928M | 19.44M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
46 | 2171688 | 24.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
25.0¢ | 1104481 | 24 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1261 | 0.270 |
1 | 100000 | 0.260 |
6 | 604503 | 0.255 |
13 | 439434 | 0.250 |
43 | 1836975 | 0.245 |
Price($) | Vol. | No. |
---|---|---|
0.120 | 163265 | 1 |
0.220 | 87297 | 1 |
0.225 | 506932 | 12 |
0.230 | 121969 | 3 |
0.235 | 78232 | 5 |
Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
Featured News
BRN (ASX) Chart |